EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins

Joshua Loya, Charlie Zhang, Emily Cox, Achal S Achrol, Santosh Kesari

CNS Oncology · 30.11.2019 · 8 (3)

DOI: 10.2217/cns-2019-0001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Oncology, online erschienen am 21.11.2019. Verfasst von Joshua Loya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wayne State University School of Medicine, Department of Neurosurgery, 42 W Warren Ave, Detroit, MI 48202, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to develop novel therapeutic strategies that can maximize tumor cell eradication while minimizing collateral side effects. Particularly, biological intratumoral therapies have been the focus of new translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two-part review will provide an overview of biological intratumoral therapies and summarize key advances and remaining challenges in intratumoral biological therapies for high-grade glioma. Part I focuses on discussion of the concepts of intratumoral delivery and immunotoxin therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBrain NeoplasmsDrug Delivery SystemsGliomaHumansImmunotoxinsInfusions, IntralesionalInjections, IntralesionalNeoplasm GradingPrognosisRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

biologic therapybrain neoplasmchemotherapydrug deliveryglioblastomahigh-grade gliomasimmunotoxinintratumoral delivery

Substanzen

Antineoplastic AgentsImmunotoxins

Autor:innen und Institutionen

  • Wayne State University School of Medicine, Department of Neurosurgery, 42 W Warren Ave, Detroit, MI 48202, USA.
  • State University of New York at Buffalo School of Medicine, 1010 Main St, Buffalo, NY 14202, USA.
  • Providence Medical Research Center, 105 W 8th Ave #6050w, Spokane, WA 99204, USA.
  • John Wayne Cancer Institute & Pacific Neuroscience Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA.

Zitieren

APA

Loya, J., Zhang, C., Cox, E., Achrol, A. S., & Kesari, S. (2019). Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. CNS Oncology, 8(3). https://doi.org/10.2217/cns-2019-0001

Vancouver

Loya J, Zhang C, Cox E, Achrol AS, Kesari S. Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. CNS Oncology. 2019;8(3). doi:10.2217/cns-2019-0001

BibTeX
@article{Loya2019,
  author = {Loya, Joshua and Zhang, Charlie and Cox, Emily and Achrol, Achal S and Kesari, Santosh},
  title = {Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins},
  journal = {CNS Oncology},
  year = {2019},
  volume = {8},
  number = {3},
  doi = {10.2217/cns-2019-0001}
}
Kostenlos starten →